Chronic Granulomatous Disease (CGD)

The Latest Clinical Trial Updates from CRISPR...
May. 14, 2025

This week's clinical update includes FDA RMAT designation to Beam Therapeutics' BEAM-302 for the treatment of alpha-1 antitrypsin deficiency as well...

The FDA Has Cleared the First Clinical Trial...
CMN Clinical

May. 1, 2024

Prime Medicine announced this week that the FDA has cleared its investigational new drug application for PM359 for the treatment of chronic...

Chronic Granulomatous Disease (CGD)

Chronic Granulomatous Disease, CGD, (NCT06325709)
Sponsors:
National Institute of Allergy and Infectious Diseases (NIAID)
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine